Vicriviroc + MK2048 + Progestin Vaginal Ring

Description: A vaginal ring whose mechanism of action is CCR5 inhibitor, integrase inhibitor and a progestin for protection against HIV and pregnancy.

Product Details

Active Pharmaceutical Ingredient (API):

Inactive material: EVA

Status Details

Developer: , ,

Status Details:
  • Phase I study of 2-ARV IVR prototype completed in 2016.
  • Merck announced that it would discontinue development of its investigational CCR5 antagonist vicriviroc for the treatment of HIV infection in both treatment-naive and treatment-experienced patients, due to unimpressive results in clinical trials.

Additional Information

Footnotes:
  • Vicriviroc is also known as MK4176.

Vertical Tabs

Print